Foundation
Medicine and ARIAD
Pharmaceuticals ARIA today announced a genomic
profiling collaboration to study AP26113, ARIAD's investigational
dual-inhibitor of ALK and EGFR in patients with non-small cell lung
cancer (NSCLC) and other cancers. Foundation Medicine will work with
ARIAD to generate genomic profile information for patients enrolled in
ARIAD's ongoing Phase 1/2 trial and these data will be matched with
clinical observations to understand the activity and selectivity profile
of AP26113.
“It is important that we have a deep molecular understanding of
patients' tumors as they begin treatment with AP26113, especially those
patients with complex prior treatment histories,” stated Timothy P.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in